Perspectives on immunotherapy in prostate cancer and solid tumors: Where is the future?

Seminars in Oncology

Volumn 40, Issue 3, 2013, Pages 347-360

  Snyder, Alexandra ^a   Tepper, Jaron E ^a   Slovin, Susan F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELAGENPUMATUCEL L; CANCER VACCINE; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOCETAXEL; GM2 VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; INTERLEUKIN 2; IPILIMUMAB; MUCIN 1; ONAMELATUCEL L; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SIPULEUCEL T; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTIBODY TITER; ARTICLE; BONE METASTASIS; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; COLITIS; COLORECTAL CANCER; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; INFLUENZA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; VIRUS LOAD;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84879431256     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.009     Document Type: Article

References (137)

1. S.P. Buchbinder, D.V. Mehrotra, and A. Duerr Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial Lancet 372 2008 1881 1893
2. S. Rerks-Ngarm, P. Pitisuttithum, and S. Nitayaphan Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand N Engl J Med 361 2009 2209 2220
3. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
4. Robertson M, Mehrotra, D, Fitzgerald, D, et al Efficacy results from the STEP study: a phase II test of Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef trivalent vaccine [abstract 88LB]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA; February, 3-6, 2008. 2008.
5. Robertson M, Casimiro, D, De Rosa S, et al Immunological characterization of subjects from the STEP Study: a phase IIB test of Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent vaccine [abstract 89LB]. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA; February, 3-6, 2008.
6. N.A. Hutnick, D.G. Carnathan, and S.A. Dubey Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells Nat Med 15 2009 876 878
7. K.L. O'Brien, J. Liu, and S.L. King Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans Nat Med 15 2009 873 875
8. G.E. Gray, M. Allen, and Z. Moodie Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study Lancet Infect Dis 11 2011 507 515
9. A. Eggermont, S. Suchiu, and W. Ruka EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results [abstract 9004] J Clin Oncol 26 2008 (May Suppl)
10. P.O. Livingston, G. Ritter, and P. Srivastava Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside Cancer Res 49 1989 7045 7050
11. P.O. Livingston, G.Y. Wong, and S. Adluri Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036 1044
12. D.L. Morton, E.C. Hsueh, and R. Essner Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes Ann Surg 236 2002 438 448
13. E.C. Hsueh, R. Essner, and L.J. Foshag Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine J Clin Oncol 20 2002 4549 4554
14. E.C. Hsueh, E. Famatiga, S. Shu, X. Ye, and D.L. Morton Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma Ann Surg Oncol 11 2004 892 899
15. E.C. Hsueh, R.K. Gupta, K. Qi, and D.L. Morton Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine J Clin Oncol 16 1998 2913 2920
16. Morton DL, Mozillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25 (18 Suppl 8508).
17. S.A. Rosenberg, M.T. Lotze, and L.M. Muul A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 316 1987 889 897
18. R.I. Fisher, C.A. Coltman Jr., and J.H. Doroshow Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial Ann Intern Med 108 1988 518 523
19. G. Fyfe, R.I. Fisher, and S.A. Rosenberg Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 1995 688 696
20. S. Negrier, B. Escudier, and C. Lasset Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med 338 1998 1272 1278
21. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
22. D. Jocham, A. Richter, and L. Hoffmann Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 2004 594 599
23. H. Soliman Developing an effective breast cancer vaccine Cancer Control 17 2010 183 190
24. G.E. Peoples, J.M. Gurney, and M.T. Hueman Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients J Clin Oncol 23 2005 7536 7545
25. J.L. Murray, M.E. Gillogly, and D. Przepiorka Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer Clin Cancer Res 8 2002 3407 3418
26. N. Leffers, T. Daemen, H.M. Boezen, K.J. Melief, and H.W. Nijman Vaccine-based clinical trials in ovarian cancer Expert Rev Vaccines 10 2011 775 784
27. S.R. Thibodeaux, and T.J. Curiel Immune therapy for ovarian cancer: promise and pitfalls Int Rev Immunol 30 2011 102 119
28. J.M. Whitworth, and R.D. Alvarez Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature Expert Opin Biol Ther 11 2011 751 762
29. R.N. Grisham, J. Berek, J. Pfisterer, and P. Sabbatini Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer Immunotherapy 3 2011 153 162
30. F.S. Hodi, M.C. Mihm, and R.J. Soiffer Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 2003 4712 4717
31. N. Leffers, T. Daemen, and W. Helfrich Antigen-specific active immunotherapy for ovarian cancer Cochrane Database Syst Rev 2010 CD007287
32. L.F. Dodson, W.G. Hawkins, and P. Goedegebuure Potential targets for pancreatic cancer immunotherapeutics Immunotherapy 3 2011 517 537
33. S. Koido, S. Homma, and A. Takahara Current immunotherapeutic approaches in pancreatic cancer Clin Dev Immunol 2011 2011 267539
34. Y. Kimura, J. Tsukada, and T. Tomoda Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma Pancreas 41 2012 195 205
35. E. Ellebaek, M.H. Andersen, I.M. Svane, and P.T. Straten Immunotherapy for metastatic colorectal cancer: present status and new options Scand J Gastroenterol 47 2012 315 324
36. J.B. Vermorken, A.M. Claessen, and H. van Tinteren Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 353 1999 345 350
37. D. O'Mahony, J.C. Morris, and C. Quinn A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clin Cancer Res 13 2007 958 964
38. M.E. O'Brien, A. Saini, and I.E. Smith A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma Br J Cancer 83 2000 853 857
39. L. Assersohn, B.E. Souberbielle, and M.E. O'Brien A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy Clin Oncol (R Coll Radiol) 14 2002 23 27
40. M.E. O'Brien, H. Anderson, and E. Kaukel SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results Ann Oncol 15 2004 906 914
41. E Neninger Vinageras, Torre A de la, M. Osorio Rodríguez, and M. Catalá Ferrer Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer J Clin Oncol 26 2008 1452 1458
42. Quoix E, Westeel V, Papai Z, et al. TG4010.09: randomized, controlled, phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer [abstract 234PD]. European Society of Medical Oncology Annual Meeting, September 12-16, 2008; Stockholm, Sweden.
43. P.A. Bradbury, and F.A. Shepherd Immunotherapy for lung cancer J Thorac Oncol 3 2008 S164 S170
44. F.A. Shepherd, J.Y. Douillard, and G.R. Blumenschein Jr Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome J Thorac Oncol 6 2011 1763 1773
45. G. Giaccone, C. Debruyne, and E. Felip Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) J Clin Oncol 23 2005 6854 6864
46. Lynch T, Neal J, Bondarenko I, et al. Phase 2 trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIB/IV non-small cell lung cancer (NSCLC)[abstract 375PD]. 35th European Society for Medical Oncology, October 8-12, 2010; Milan, Italy.
47. G.J. Freeman, A.J. Long, and Y. Iwai Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
48. H. Dong, S.E. Strome, and D.R. Salomao Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
49. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
50. S.L. Topalian, S.F. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti -PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
51. J.R. Brahmer, C.G. Drake, and I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
52. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
53. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
54. V. Jeet, P.J. Russell, and A. Khatri Modeling prostate cancer: a perspective on transgenic mouse models Cancer Metastasis Rev 29 2010 123 142
55. W.F. Dunning Prostate cancer in the rat Natl Cancer Inst Monogr 12 1963 351 369
56. M. Pollard Lobund-Wistar rat model of prostate cancer in man Prostate 37 1998 1 4
57. J. Obradovich, R. Walshaw, and E. Goullaud The influence of castration on the development of prostatic carcinoma in the dog. 43 cases (1978-1985) J Vet Intern Med 1 1987 183 187
58. A. Rangarajan, and R.A. Weinberg Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice Nat Rev Cancer 3 2003 952 959
59. B.A. Foster, J.R. Gingrich, E.D. Kwon, C. Madias, and N.M. Greenberg Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model Cancer Res 57 1997 3325 3330
60. V. Jeet, K. Ow, and E. Doherty Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer Prostate 68 2008 548 562
61. A.A. Hurwitz, B.A. Foster, and E.D. Kwon Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Res 60 2000 2444 2448
62. Z. Liu, I.E. Eltoum, and B. Guo Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer J Immunol 180 2008 6044 6053
63. D.J. Waters, W.A. Sakr, and D.W. Hayden Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates Prostate 36 1998 64 67
64. J.N. Mubiru, G.B. Hubbard, and E.J. Dick Jr. Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases Prostate 68 2008 1546 1554
65. L.S. Kean, S. Gangappa, T.C. Pearson, and C.P. Larsen Transplant tolerance in non-human primates: progress, current challenges and unmet needs Am J Transplant 6 2006 884 893
66. A.D. Kirk Crossing the bridge: large animal models in translational transplantation research Immunol Rev 196 2003 176 196
67. S. Baenziger, R. Tussiwand, and E. Schlaepfer Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice Proc Natl Acad Sci U S A 103 2006 15951 15956
68. Z. Ambrose, V.N. KewalRamani, P.D. Bieniasz, and T. Hatziioannou HIV/AIDS: in search of an animal model Trends Biotechnol 25 2007 333 337
69. S. Slovin Chemotherapy and immunotherapy combination in advanced prostate cancer Clin Adv Hematol Oncol 10 2012 90 100
70. F. Dayyani, G.E. Gallick, C.J. Logothetis, and P.G. Corn Novel therapies for metastatic castrate-resistant prostate cancer J Natl Cancer Inst 103 2011 1665 1675
71. E. Cha, and L. Fong Immunotherapy for prostate cancer: biology and therapeutic approaches J Clin Oncol 29 2011 3677 3685
72. M. Bilusic, C. Heery, and R.A. Madan Immunotherapy in prostate cancer: emerging strategies against a formidable foe Vaccine 29 2011 6485 6497
73. G. Attard, J. Richards, and J.S. de Bono New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway Clin Cancer Res 17 2011 1649 1657
74. G. Di Lorenzo, C. Buonerba, and P.W. Kantoff Immunotherapy for the treatment of prostate cancer Nat Rev Clin Oncol 8 2011 551 561
75. D.G. McNeel, E.J. Dunphy, and J.G. Davies Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer J Clin Oncol 27 2009 4047 4054
76. Q. Ma, M. Safar, and E. Holmes Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy Prostate 61 2004 12 25
77. T.P. Gade, W. Hassen, and E. Santos Targeted elimination of prostate cancer by genetically directed human T lymphocytes Cancer Res 65 2005 9080 9098
78. A. Morgenroth, M. Cartellieri, and M. Schmitz Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells Prostate 67 2007 1121 1131
79. C.S. Higano A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic castration-resistant prostate cancer (CRPC) Genitourinary Cancers Symp LBA150 2009
80. Small E, Demkow T, Gerritsen WR, et?al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract]. ASCO Genitourinary Cancers Symposium. February 26-28, 2009, Orlando, FL.
81. P.W. Kantoff, T.J. Schuetz, and B.A. Blumenstein Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
82. J.L. Gulley, P.M. Arlen, and R.A. Madan Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunol Immunother 59 2010 663 674
83. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094
84. C.S. Higano, P.F. Schellhammer, and E.J. Small Integrated data from 2?randomized, double-blind, placebo-controlled, phase 3?trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
85. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
86. C.G. Drake Immunotherapy for prostate cancer: an emerging treatment modality Urol Clin North Am 37 2010 121 129
87. J.W. Simons, B. Mikhak, and J.F. Chang Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex?vivo gene transfer Cancer Res 59 1999 5160 5168
88. C.S. Higano, J.M. Corman, and D.C. Smith Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer Cancer 113 2008 975 984
89. A.J. van den Eertwegh, J. Versluis, and H.P. van den Berg Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol 13 2012 509 517
90. M.L. Huber, L. Haynes, C. Parker, and P. Iversen Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer J Natl Cancer Inst 104 2012 273 279
91. G. Pawelec, J. Lustgarten, C. Ruby, and C. Gravekamp Impact of aging on cancer immunity and immunotherapy Cancer Immunol Immunother 58 2009 1907 1908
92. B. Grubeck-Loebenstein, S. Della Bella, and A.M. Iorio Immunosenescence and vaccine failure in the elderly Aging Clin Exp Res 21 2009 201 209
93. D.D. Taub, and D.L. Longo Insights into thymic aging and regeneration Immunol Rev 205 2005 72 93
94. T. Fulop, R. Kotb, and C.F. Fortin Potential role of immunosenescence in cancer development Ann N Y Acad Sci 1197 2010 158 165
95. B.A. E.S. Tjoa, and V.A. Bowes Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides Prostate 32 4 1997 272 278
96. P.A. Lodge, L.A. Jones, R.A. Bader, G.P. Murphy, and M.L. Salgaller Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial Cancer Res 60 2000 829 833
97. K.N. Kodumudi, K. Woan, and D.L. Gilvary A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers Clin Cancer Res 16 2010 4583 4594
98. L. Zitvogel, L. Apetoh, and F. Ghiringhelli The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118 2008 1991 2001
99. D.P. Petrylak, P.F. Schellhammer, E. Small, and M.W. Frohlich Androgen independent prostate cancer (AIPC) patients who receive sipuleucel-T followed by docetaxel have prolonged survival Am Urolog Assoc Ann Metg (American Urology Association Meeting Abstracts) 2007 605
100. Petrylak DP. Defining the optimal role of immunotherapy & chemotherapy. Chemotherapy Foundation Symposium XXIV. November 8-11, 2006; New York, NY.
101. R.A. Madan, J.L. Gulley, and J. Schlom Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy Clin Cancer Res 14 2008 4526 4531
102. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
103. E.D. Kwon, A.A. Hurwitz, and B.A. Foster Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer Proc Natl Acad Sci U S A 94 1997 8099 8103
104. R.A. Madan, M. Mohebtash, and P.M. Arlen Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol 13 2012 501 508
105. M.J. Morris, M.I. Milowsky, and N. Pandit-Tasker Phase 2?trial of 177 lutetium (177Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (177Lu-J591) in patients (pts) with metastatic androgen independent prostate cancer (abstract) J Clin Oncol 24 2006 244s
106. M.I. Milowsky, D.M. Nanus, and L. Kostakoglu Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer J Clin Oncol 22 2004 2522 2531
107. D. Ma, C.E. Hopf, and A.D. Malewicz Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen Clin Cancer Res 12 2006 2591 2596
108. M.I. Milowsky, M. Galsky, and D.J. George Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (abstract) J Clin Oncol 24 2006 217s
109. C.L. Finstad, C.Y. Wang, and J. Kowalski Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy Vaccine 22 2004 1300 1313
110. A. Ben Jemaa, Y. Bouraoui, and S. Sallami Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies J Exp Clin Cancer Res 29 2010 171
111. R.A. Madan, J.L. Gulley, T. Fojo, and W.L. Dahut Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression Oncologist 15 2010 969 975
112. A. Hoos, A.M. Eggermont, and S. Janetzki Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 102 2010 1388 1397
113. S.F. Slovin Are we trumping bone disease in prostate cancer? Oncology (Williston Park) 25 2011 1390 1393
114. E. Sato, S.H. Olson, and J. Ahn Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci U S A 102 2005 18538 18543
115. J. Galon, A. Costes, and F. Sanchez-Cabo Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
116. F. Pages, A. Berger, and M. Camus Effector memory T cells, early metastasis, and survival in colorectal cancer N Engl J Med 353 2005 2654 2666
117. Y. Naito, K. Saito, and K. Shiiba CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer Cancer Res 58 1998 3491 3494
118. T.J. Curiel, G. Coukos, and L. Zou Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949
119. N. Hiraoka, K. Onozato, T. Kosuge, and S. Hirohashi Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions Clin Cancer Res 12 2006 5423 5434
120. P. Salama, M. Phillips, and F. Grieu Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer J Clin Oncol 27 2009 186 192
121. C. Badoual, S. Hans, and J. Rodriguez Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers Clin Cancer Res 12 2006 465 472
122. S. Vesalainen, P. Lipponen, M. Talja, and K. Syrjanen Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma Eur J Cancer 30A 1994 1797 1803
123. P.A. McArdle, K. Canna, and D.C. McMillan The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer Br J Cancer 91 2004 541 543
124. M. Mercader, B.K. Bodner, and M.T. Moser T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci U S A 98 2001 14565 14570
125. J.S. Sutherland, G.L. Goldberg, and M.V. Hammett Activation of thymic regeneration in mice and humans following androgen blockade J Immunol 175 2005 2741 2753
126. C. Sorrentino, P. Musiani, P. Pompa, G. Cipollone, and E. Di Carlo Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients Clin Cancer Res 17 2011 1571 1581
127. C.M. Robbins, W.A. Tembe, and A. Baker Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors Genome Res 21 2011 47 55
128. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat Rev Immunol 10 2010 787 796
129. A.J. Pollard, K.P. Perrett, and P.C. Beverley Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines Nat Rev Immunol 9 2009 213 220
130. L.R. Bulkow, R.B. Wainwright, G.W. Letson, S.J. Chang, and J.I. Ward Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants Pediatr Infect Dis J 12 1993 484 492
131. K.L. Sleeman, L. Daniels, and M. Gardiner Acquisition of Streptococcus pneumoniae and nonspecific morbidity in infants and their families: a cohort study Pediatr Infect Dis J 24 2005 121 127
132. G.T. Jennings, and M.F. Bachmann Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines Curr Mol Med 7 2007 143 155
133. L.A. Myc, A. Gamian, and A. Myc Cancer vaccines Any future? Arch Immunol Ther Exp (Warsz) 59 2011 249 259
134. S.M. Levitz, and D.T. Golenbock Beyond empiricism: informing vaccine development through innate immunity research Cell 148 2012 1284 1292
135. D.S. Hsu, M.K. Kim, and B.S. Balakumaran Immune signatures predict prognosis in localized cancer Cancer Invest 28 2010 765 773
136. A.B. Glinskii, J. Ma, and S. Ma Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders Cell Cycle 8 2009 3925 3942
137. S.F. Slovin, T. Beer, and S. Higano Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract] J Clin Oncol 27 2009 5138